Harbin Pharmaceutical Group Co

Harbin Pharmaceutical Group Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Harbin Pharmaceutical Group Co (600664.SS) as of Oct 16, 2026 is 730.51 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 1.05 B CNY — a change of -30.31% (lower).

EBITDA

730.51 MCNY

YoY

-30.31%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Harbin Pharmaceutical Group Co is 2025 730.51 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Harbin Pharmaceutical Group Co was 2024 1.05 B CNY. It decreases by -30.31% lower compared to the previous year.

The Harbin Pharmaceutical Group Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
667.37 M CNY
Jan 1, 2019
425.74 M CNY
Jan 1, 2020
-810.11 M CNY
Jan 1, 2021
826.93 M CNY
Jan 1, 2022
879.55 M CNY
Jan 1, 2023
826.33 M CNY
Jan 1, 2024
1.05 B CNY
Jan 1, 2025
730.51 M CNY
The Harbin Pharmaceutical Group Co EBITDA history
YEAREBITDAYoY
730.51 MCNY-30.31%
1.05 BCNY+26.85%
826.33 MCNY-6.05%
879.55 MCNY+6.36%
826.93 MCNY-202.08%
-810.11 MCNY-290.28%
425.74 MCNY-36.21%
667.37 MCNY-15.19%
786.90 MCNY-29.12%
1.11 BCNY+29.49%
857.31 MCNY+88.38%
455.10 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Harbin Pharmaceutical Group Co Stock analysis

What does Harbin Pharmaceutical Group Co do? Harbin Pharmaceutical Group Co Ltd is a pharmaceutical company based in Harbin, China, operating within the Health Care sector. The company engages in the research, development, manufacture, wholesale, and retail of pharmaceutical products. It has 10,064 employees, with its headquarters located in Harbin, Heilongjiang Province. Founded through an IPO on June 29, 1993, the company is listed on the Shanghai Stock Exchange under the ticker 600664.SS. Harbin Pharmaceutical Group's primary business activities include innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals. The company operates across multiple sectors including antibiotics, over-the-counter drugs, health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. Its product portfolio features calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, and Xingaizhonggai high calcium tablets. The company's website is https://www.hayao.com/, though the source description provided is untrusted and should not be relied upon for factual accuracy. Harbin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Harbin Pharmaceutical Group Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Harbin Pharmaceutical Group Co is 730.51 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Harbin Pharmaceutical Group Co changed from 1.05 B CNY to 730.51 M CNY, representing a -30.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Harbin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Harbin Pharmaceutical Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Harbin Pharmaceutical Group Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Harbin Pharmaceutical Group Co